LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced preliminary revenue results for the second quarter ended December 31, 2024, and raised its fiscal 2025 revenue guidance.
Preliminary Second Quarter Fiscal 2025 Highlights:
Revenue of approximately $67.5 million, an increase of 31% from the prior year period, and up 43% sequentially from the first fiscal quarter
Active Account growth in the Americas of 22.7% in comparison to the prior year period, and up 25.4% sequentially from the first fiscal quarter
Active Account growth of 12.1% globally in comparison to the prior year period, and up 18.5% sequentially from the first fiscal quarter
Fiscal 2025 Guidance:
The Company now expects revenue in the range of $235 million to $245 million in fiscal 2025 compared to prior revenue guidance of $200 million to $210 million
“Second quarter revenue results were exceptional, reflecting strong sales of the MindBody GLP-1 System™ we launched in October in the United States along with outstanding execution by our team to quickly ramp supply chain and fulfillment capacity to meet the robust demand,”
said Steve Fife, President and CEO of LifeVantage.
“We also saw significant growth in Active Accounts driven by the highest number